U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H24N8O4S
Molecular Weight 508.5548
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of FIMEPINOSTAT

SMILES

CN(Cc1cc2c(c(nc(-c3ccc(nc3)OC)n2)N4CCOCC4)s1)c5ncc(cn5)C(=NO)O

InChI

InChIKey=JOWXJLIFIIOYMS-UHFFFAOYSA-N
InChI=1S/C23H24N8O4S/c1-30(23-25-11-15(12-26-23)22(32)29-33)13-16-9-17-19(36-16)21(31-5-7-35-8-6-31)28-20(27-17)14-3-4-18(34-2)24-10-14/h3-4,9-12,33H,5-8,13H2,1-2H3,(H,29,32)

HIDE SMILES / InChI

Molecular Formula C23H24N8O4S
Molecular Weight 508.5548
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/22693356

CUDC-907 is a small molecule inhibitor of histone deacetylase and PI3 kinase developed by Curis. It is investigated in clinical trials for the treatment of relapsed or refractory lymphomas, thyroid cancer, multiple myeloma, breast cancer and other malignancies.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.7 nM [IC50]
1.8 nM [IC50]
2.8 nM [IC50]
Target ID: P42336
Gene ID: 5290.0
Gene Symbol: PIK3CA
Target Organism: Homo sapiens (Human)
19.0 nM [IC50]
Target ID: O00329
Gene ID: 5293.0
Gene Symbol: PIK3CD
Target Organism: Homo sapiens (Human)
39.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.
2012 Aug 1
Patents

Sample Use Guides

The recommended dose for phase 2 clinical trial is 60 mg on the 5/2 dosing schedule.
Route of Administration: Oral
Human cancer cell lines were purchased from American Type Culture Collection (Manassas, VA) and plated at densities of 5,000 to 10,000 per well in 96-well flat-bottomed plates with the recommended culture medium. The cells were then incubated with compounds at various concentrations for 72 hours in culture medium supplemented with 0.5% (v/v) FBS. Growth inhibition was assessed by assay of cellular ATP content using the Perkin-Elmer ATPlite kit. CUDC-907 inhibits the growth of cell lines with IC50 of 10-100 nM.
Substance Class Chemical
Created
by admin
on Sat Jun 26 10:15:47 UTC 2021
Edited
by admin
on Sat Jun 26 10:15:47 UTC 2021
Record UNII
3S9RX35S5X
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
FIMEPINOSTAT
USAN   INN  
Official Name English
N-HYDROXY-2-(((2-(6-METHOXYPYRIDIN-3-YL)-4-(MORPHOLIN-4-YL)THIENO(3,2-D)PYRIMIDIN-6-YL)METHYL)(METHYL)AMINO)PYRIMIDINE-5-CARBOXAMIDE
Systematic Name English
FIMEPINOSTAT [USAN]
Common Name English
FIMEPINOSTAT [INN]
Common Name English
5-PYRIMIDINECARBOXAMIDE, N-HYDROXY-2-(((2-(6-METHOXY-3-PYRIDINYL)-4-(4-MORPHOLINYL)THIENO(3,2-D)PYRIMIDIN-6-YL)METHYL)METHYLAMINO)-
Systematic Name English
PI3K/HDAC INHIBITOR CUDC-907
Common Name English
CUDC907
Code English
CUDC-907
Code English
FIMEPINOSTAT [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C129825
Created by admin on Sat Jun 26 10:15:47 UTC 2021 , Edited by admin on Sat Jun 26 10:15:47 UTC 2021
NCI_THESAURUS C1404
Created by admin on Sat Jun 26 10:15:47 UTC 2021 , Edited by admin on Sat Jun 26 10:15:47 UTC 2021
NCI_THESAURUS C1946
Created by admin on Sat Jun 26 10:15:47 UTC 2021 , Edited by admin on Sat Jun 26 10:15:47 UTC 2021
FDA ORPHAN DRUG 467814
Created by admin on Sat Jun 26 10:15:47 UTC 2021 , Edited by admin on Sat Jun 26 10:15:47 UTC 2021
FDA ORPHAN DRUG 482415
Created by admin on Sat Jun 26 10:15:47 UTC 2021 , Edited by admin on Sat Jun 26 10:15:47 UTC 2021
Code System Code Type Description
EPA CompTox
1339928-25-4
Created by admin on Sat Jun 26 10:15:47 UTC 2021 , Edited by admin on Sat Jun 26 10:15:47 UTC 2021
PRIMARY
INN
10504
Created by admin on Sat Jun 26 10:15:47 UTC 2021 , Edited by admin on Sat Jun 26 10:15:47 UTC 2021
PRIMARY
DRUG BANK
DB11891
Created by admin on Sat Jun 26 10:15:47 UTC 2021 , Edited by admin on Sat Jun 26 10:15:47 UTC 2021
PRIMARY
CAS
1339928-25-4
Created by admin on Sat Jun 26 10:15:47 UTC 2021 , Edited by admin on Sat Jun 26 10:15:47 UTC 2021
PRIMARY
FDA UNII
3S9RX35S5X
Created by admin on Sat Jun 26 10:15:47 UTC 2021 , Edited by admin on Sat Jun 26 10:15:47 UTC 2021
PRIMARY
PUBCHEM
54575456
Created by admin on Sat Jun 26 10:15:47 UTC 2021 , Edited by admin on Sat Jun 26 10:15:47 UTC 2021
PRIMARY
ChEMBL
CHEMBL3545052
Created by admin on Sat Jun 26 10:15:47 UTC 2021 , Edited by admin on Sat Jun 26 10:15:47 UTC 2021
PRIMARY
NCI_THESAURUS
C104008
Created by admin on Sat Jun 26 10:15:47 UTC 2021 , Edited by admin on Sat Jun 26 10:15:47 UTC 2021
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
TARGET -> INHIBITOR
CUDC-907 is a dual PI3K.ALPHA. and HDAC1 inhibitor. Phase 1.
INHIBITOR
IC50
TARGET -> INHIBITOR
CUDC-907 is a dual PI3K.ALPHA. and HDAC2 inhibitor. Phase 1.
INHIBITOR
IC50
TARGET -> INHIBITOR
CUDC-907 is a dual PI3K.ALPHA. and HDAC3 inhibitor. Phase 1.
INDUCER
IC50
TARGET -> INHIBITOR
CUDC-907 is a dual PI3K.ALPHA. and HDAC10 inhibitor. Phase 1.
INHIBITOR
IC50
Related Record Type Details
ACTIVE MOIETY